Drug intelligence / Profile preview

KY-2

Development stage: Preclinical
Lead developer: Shenzhen KeYe Life Technologies
Modality: Small Molecules
Administration: Oral

Overview

KY-2 is an orally bioavailable small molecule inhibitor of the eukaryotic initiation factor 4A (eIF4A) RNA helicase, currently in preclinical development by Keye Life Sciences (Kaiyue Biotech). eIF4A is a key component of the eIF4F complex, which is responsible for the recruitment of ribosomes to mRNA. By inhibiting eIF4A, KY-2 disrupts the translation of mRNAs with complex 5' untranslated regions (UTRs), which often encode potent oncogenes and survival factors such as MYC, BCL2, and cyclin D1. This mechanism is particularly relevant for treating late-stage solid tumors and gastrointestinal cancers where dysregulated protein synthesis drives tumor progression and resistance.

Targets

EIF4A2 (Eukaryotic translation initiation factor 4A2)

Beyond the preview

Go deeper on KY-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KY-2.

Explore the full profile